Glenmark Pharmaceuticals has informed that it attached media release titled ‘Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials’.
The above information is a part of company’s filings submitted to BSE.